Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. Makes A New $2.68M Investment In Johnson & Johnson (NYSE:JNJ)

Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 18,300 shares of the company’s stock, valued at approximately $2,675,000. Johnson & Johnson is 33.9% of Mitsubishi UFJ Morgan Stanley Securities Co.’s holdings. Ltd., making the stock the second largest position.

Other institutional investors have also made changes to their positions in the company. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at about $4,071,642,000. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after purchasing another 3,391,657 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Johnson & Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock valued at $3,453,978,000 after acquiring an additional 3,139,499 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 15,945,533 shares of the company’s stock valued at $2,483,532,000 after purchasing an additional 241,799 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Johnson & Johnson by 10.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 10,169,190 shares of the company’s stock worth $1,593,908,000 after buying an additional 975,485 shares during the last quarter. 69.55% of shares are currently owned by institutional investors.

Insider buying and selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. Insiders own 0.16% of the company’s shares.

Johnson & Johnson trading rose 0.1%

NYSE JNJ opened at $167.27 on Thursday. The firm has a market cap of $402.57 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. The company’s 50-day moving average price is $156.82, and its two-hundred-day moving average price is $153.70. The company has a current ratio of 1.07, a quick ratio of 0.85, and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same period last year, the company posted earnings of $2.80 per share. The company’s revenue rose 4.3% year-over-year. On average, analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, August 27. This represents an annualized dividend of $4.96 and a yield of 2.97%. Johnson & Johnson’s payout ratio is 30.92%.

The Wall Street analyst weighs in

Several equities analysts have recently issued reports on JNJ shares. Goldman Sachs Group cut their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Morgan Stanley boosted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. TD Cowen cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Moderate Buy” and a consensus price target of $173.21, based on data from MarketBeat.com.

See the latest stock report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Read more

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.